CD26 Enhances Cancer Cell Sensitivity to Treatment
Author Information
Author(s): K Sato, U Aytac, T Yamochi, K Ohnuma, K S McKee, C Morimoto, NH Dang
Primary Institution: MD Anderson Cancer Center
Hypothesis
Does CD26/dipeptidyl peptidase IV enhance the expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors?
Conclusion
The presence of CD26/DPPIV enhances sensitivity to apoptosis induced by topoisomerase II inhibitors, which may be exploited for future cancer treatments.
Supporting Evidence
- CD26 Jurkat transfectants showed increased sensitivity to etoposide and doxorubicin.
- Enhanced apoptosis was linked to increased cleavage of apoptotic proteins.
- CD26 presence was associated with higher topoisomerase II alpha expression.
Takeaway
CD26 helps cancer cells die when treated with certain drugs, making them more effective in fighting cancer.
Methodology
The study involved using Jurkat T-cell leukaemia stable transfectants to assess the effects of CD26/DPPIV on apoptosis induced by doxorubicin and etoposide.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website